PMID- 36246378 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221019 IS - 2296-4185 (Print) IS - 2296-4185 (Electronic) IS - 2296-4185 (Linking) VI - 10 DP - 2022 TI - Chondrogenic differentiation of mesenchymal stem cells through cartilage matrix-inspired surface coatings. PG - 991855 LID - 10.3389/fbioe.2022.991855 [doi] LID - 991855 AB - The stem cell niche comprises soluble molecules and extracellular matrix components which provide chemical and mechanical cues that determine the differentiation of stem cells. Here, the effect of polyelectrolyte multilayer (PEM) composition and terminal layer fabricated with layer-by-layer technique (LBL) pairing either hyaluronan [in its native (nHA) and oxidized form (oHA)] or chondroitin sulfate (CS) with type I collagen (Col I) is investigated on chondrogenic differentiation of human umbilical mesenchymal stem cells (hUC-MSCs). Physical studies performed to investigate the establishment and structure of the surface coatings show that PEM composed of HA and Col I show a dominance of nHA or oHA with considerably lesser organization of Col I fibrils. In contrast, distinguished fibrilized Col I is found in nCS-containing PEM. Generally, Col I-terminated PEM promote the adhesion, migration, and growth of hUC-MSCs more than GAG-terminated surfaces due to the presence of fibrillar Col I but show a lower degree of differentiation towards the chondrogenic lineage. Notably, the Col I/nHA PEM not only supports adhesion and growth of hUC-MSCs but also significantly promotes cartilage-associated gene and protein expression as found by histochemical and molecular biology studies, which is not seen on the Col I/oHA PEM. This is related to ligation of HA to the cell receptor CD44 followed by activation of ERK/Sox9 and noncanonical TGF-beta signaling-p38 pathways that depends on the molecular weight of HA as found by immune histochemical and western blotting. Hence, surface coatings on scaffolds and other implants by PEM composed of nHA and Col I may be useful for programming MSC towards cartilage regeneration. CI - Copyright (c) 2022 Zhao, Gao, Wei, Tu, Zheng, Jing, Chu, Ye and Groth. FAU - Zhao, Mingyan AU - Zhao M AD - Stem Cell Research and Cellular Therapy Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China. FAU - Gao, Xiang AU - Gao X AD - Stem Cell Research and Cellular Therapy Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China. FAU - Wei, Jinsong AU - Wei J AD - Department of Spinal Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China. FAU - Tu, Chenlin AU - Tu C AD - Stem Cell Research and Cellular Therapy Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China. AD - Department of Spinal Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China. FAU - Zheng, Hong AU - Zheng H AD - Department of Spinal Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China. FAU - Jing, Kaipeng AU - Jing K AD - Key Laboratory of Prevention and Management of Chronic Kidney Disease of Zhanjiang City, Institute of Nephrology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China. FAU - Chu, Jiaqi AU - Chu J AD - Stem Cell Research and Cellular Therapy Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China. FAU - Ye, Wei AU - Ye W AD - Department of Obstetrics and Gynecology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China. FAU - Groth, Thomas AU - Groth T AD - Department Biomedical Materials, Institute of Pharmacy, Martin Luther University Halle Wittenberg, Halle (Saale), Germany. LA - eng PT - Journal Article DEP - 20220929 PL - Switzerland TA - Front Bioeng Biotechnol JT - Frontiers in bioengineering and biotechnology JID - 101632513 PMC - PMC9557131 OTO - NOTNLM OT - ERK/Sox9 pathway OT - biomimetic multilayers OT - chondrogenesis OT - microenvironment OT - noncanonical TGF-beta pathway COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/10/18 06:00 MHDA- 2022/10/18 06:01 PMCR- 2022/01/01 CRDT- 2022/10/17 04:30 PHST- 2022/07/12 00:00 [received] PHST- 2022/09/14 00:00 [accepted] PHST- 2022/10/17 04:30 [entrez] PHST- 2022/10/18 06:00 [pubmed] PHST- 2022/10/18 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 991855 [pii] AID - 10.3389/fbioe.2022.991855 [doi] PST - epublish SO - Front Bioeng Biotechnol. 2022 Sep 29;10:991855. doi: 10.3389/fbioe.2022.991855. eCollection 2022.